Phosphate binders in patients with chronic kidney disease: Between the new and the old.

2019 ◽  
pp. 2-3
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Estimated Glomerular Filtration Rate ◽  
Chronic Kidney Disease Stage ◽  
Disease Stage ◽  
Phosphate Binders ◽  
Advanced Chronic Kidney Disease ◽  
Phosphate Retention ◽  
Stage 4 ◽  
Dietary Phosphate

Impaired phosphate excretion by the kidney leads to Hyperphosphatemia. It is an independent predictor of cardiovascular disease and mortality in patients with advanced chronic kidney disease (stage 4 and 5) particularly in case of dialysis. Phosphate retention develops early in chronic kidney disease (CKD) due to the reduction in the filtered phosphate load. Overt hyperphosphatemia develops when the estimated glomerular filtration rate (eGFR) falls below 25 to 40 mL/min/1.73 m2. Hyperphosphatemia is typically managed with oral phosphate binders in conjunction with dietary phosphate restriction. These drugs aim to decrease serum phosphate by binding ingested phosphorus in the gastrointestinal tract and its transformation to non-absorbable complexes [1].

scholarly journals Calcium, Phosphorus and PTH in Patients with End Stage of Chronic Kidney Disease, Undergoing Hemodialysis

2020 ◽  
Vol 3 (2) ◽  
pp. 21
Author(s):  
Serfa Faja ◽  
Amir Shoshi
Keyword(s):  
Chronic Kidney Disease ◽  
Vitamin D ◽  
Kidney Disease ◽  
Estimated Glomerular Filtration Rate ◽  
Treatment Options ◽  
Chronic Kidney Disease Stage ◽  
Disease Stage ◽  
Phosphate Binders ◽  
Calcium Phosphorus ◽  
End Stage

Renal hyperparathyroidism (rHPT) is a common complication of chronic kidney disease characterized by elevated parathyroid hormone levels secondary to derangements in the homeostasis of calcium, phosphate, and vitamin D. Patients with rHPT experience increased rates of cardiovascular problems and bone disease. The Kidney Disease: Improving Global Outcomes guidelines recommend that screening and management of rHPT be initiated for all patients with chronic kidney disease stage 3 (estimated glomerular filtration rate, - 60 mL/min/1.73 m2). Since the 1990s, improving medical management with vitamin D analogs, phosphate binders, and calcimimetic drugs has expanded the treatment options for patients with rHPT, but some patients still require a parathyroidectomy to mitigate the sequelae of this challenging disease.

scholarly journals Hubungan Gagal Ginjal Kronik Tingkat 4 Dan 5 Dengan Kejadian Dislipidemia Pada Pasien Gagal Ginjal Kronik Di Rumah Sakit Umum Pusat Fatmawati Periode Tahun 2016

2018 ◽  
Vol 12 (2) ◽  
Author(s):  
Dimas Farhan Wibawanto ◽  
Salman Paris ◽  
Maria Selvester Thadeus
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
High Density Lipoprotein ◽  
Low Density Lipoprotein ◽  
Chronic Kidney Disease Stage ◽  
Density Lipoprotein ◽  
Disease Stage ◽  
Low Density ◽  
Stage 4 ◽  
Relationship Of

Dyslipidemia is a common complication of chronic kidney disease. Dyslipidemia itself is a common risk for a cardiovascular disease, which is the leading cause of death in chronic kidney disease. This study aims to identify the relationship of chronic kidney disease stage 4 and 5 with the incidence of dyslipidemia at Fatmawati General Hospital in the period of 2016. Design cross-sectional with simple random sampling technique. Data were collected by looking at the patient's medical records. Respondents are 80 people. The study population were all patients diagnosed with chronic kidney disease at Fatmawati Central General Hospital in 2016. The results showed that most chronic kidney disease stage 4 has normal level of low density lipoprotein as many 22 people (73.33%) while at stage 5 most have high level of low density lipoprotein high as many 36 people (72%). High density lipoprotein obtained in patients with chronic kidney disease stage 4 mostly had normal level as many 20 people (66.67%) for stage 5 mostly had low level as many 33 people (66%). Mean lipid values of triglyceride X̄ = 152,36, high density lipoprotein X̄ = 39,36 and low density lipoprotein X̄ = 145,01. Result of bivariate analysis with chi square test showed significant relationship of chronic kidney disease stage 4 and 5 with incidence of dyslipidemia (p = 0,002).

Sign in / Sign up

Export Citation Format

Share Document